The Drug Discovery by NanoMedicine and its Clinical Experience

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387

Duncan, 2003, The dawning era of polymer therapeutics, Nat Rev, 2, 347

Maeda, 2011, EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy, Adv Drug Deliv Rev, 63, 129, 10.1016/j.addr.2010.05.001

Courtice, 1963, The origin of lipoprotein in lymph, Lymph and the Lymphatic System, 89

Iwai, 1984, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image, Cancer, 44, 2115

Tammela, 2010, Lymphangiogenesis: molecular mechanisms and future promise, Cell, 140, 460, 10.1016/j.cell.2010.01.045

Gabison, 2001, Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy, Cancer Invest, 19, 424, 10.1081/CNV-100103136

Gradishar, 2005, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, Clin J Oncol, 23, 7794, 10.1200/JCO.2005.04.937

Matsumura, 2009, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles, Cancer Sci, 100, 572, 10.1111/j.1349-7006.2009.01103.x

Duncan, 2006, Polymer conjugates as anticancer nanomedicines, Nat Rev Cancer, 6, 688, 10.1038/nrc1958

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat Nanotech, 2, 751, 10.1038/nnano.2007.387

Dvorak, 1986, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N Engl J Med, 315, 1650, 10.1056/NEJM198612253152606

Minchinton, 2006, Drug penetration in solid tumors, Nat Rev Cancer, 6, 583, 10.1038/nrc1893

Trédan, 2007, Drug resistance and the solid tumor microenvironment, J Natl Cancer Inst, 99, 1441, 10.1093/jnci/djm135

Ghajar, 2008, Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging, Histochem Cell Biol, 130, 1105, 10.1007/s00418-008-0537-1

Cabral, 2011, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size, Nat Nanotech, 6, 815, 10.1038/nnano.2011.166

Yasunaga, 2011, Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue, Bioconjug Chem, 22, 1776, 10.1021/bc200158j

Yasunaga, 2011, New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots, Cancer Sci, 102, 1396, 10.1111/j.1349-7006.2011.01954.x

Matsumura, 2012, Cancer stromal targeting (CAST) therapy, Adv Drug Deliv Rev, 64, 710, 10.1016/j.addr.2011.12.010

Maeda, 1988, Purification and identification of (hydroxyprolyl3)-bradykinin in ascitic fluid from a patient with gastric cancer, J Biol Chem, 263, 16051, 10.1016/S0021-9258(18)37555-0

Matsumura, 1988, Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue, Jpn J Cancer Res, 79, 1327, 10.1111/j.1349-7006.1988.tb01563.x

Senger, 1983, Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid, Science, 21, 983, 10.1126/science.6823562

Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381

Dvorak, 2006, Malignancy and hemostasis, Hemostasis and Thrombosis: Basic principles and Clinical Practice, 5th edn, 851

Trousseau, 1865, Pegmasia alba dolens

Stein, 2006, Incidence of venous thromboembolism in patients hospitalized with cancer, Am J Med, 119, 60, 10.1016/j.amjmed.2005.06.058

Khayat, 2000, Taxol in the management of cancers of the breast and the ovary, Cancer Invest, 18, 242, 10.3109/07357900009031828

Carney, 1996, Chemotherapy in the management of patients with inoperable non-small cell lung cancer, Semin Oncol, 23, 71

Weiss, 1990, Hypersensitivity reactions from taxol, J Clin Oncol, 8, 1263, 10.1200/JCO.1990.8.7.1263

Rowinsky, 1993, Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting, J Clin Oncol, 11, 2010, 10.1200/JCO.1993.11.10.2010

Yokoyama, 1991, Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood, Cancer Res, 51, 3229

Hamaguchi, 2005, NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel, Br J Cancer, 92, 1240, 10.1038/sj.bjc.6602479

Hamaguchi, 2007, A phase i and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation, Br J Cancer, 97, 170, 10.1038/sj.bjc.6603855

Kato, 2012, Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer., Invest New Drugs, 30, 1621, 10.1007/s10637-011-9709-2

Horwich, 1997, Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial, J Clin Oncol,, 15, 1844, 10.1200/JCO.1997.15.5.1844

Roth, 1996, Chemotherapy for advanced bladder cancer, Semin Oncol, 23, 633

Pinzani, 1994, Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review, Cancer Chemother Pharmacol, 35, 1, 10.1007/BF00686277

Cleare, 1978, Anti-tumor platinum complexes: relationships between chemical properties and activity, Biochimie, 60, 835, 10.1016/S0300-9084(78)80568-9

du Bois, 2003, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J Natl Cancer Inst, 95, 1320, 10.1093/jnci/djg036

Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069

Bellmunt, 1997, Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma, Cancer, 80, 1966, 10.1002/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W

Nishiyama, 2003, Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice, Cancer Res, 63, 8977

Uchino, 2005, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats, Br J Cancer, 93, 678, 10.1038/sj.bjc.6602772

Plummer, 2011, A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours, Br J Cancer, 104, 593, 10.1038/bjc.2011.6

Su, Phase I/II study of NC-6004, a novel micellar formulation of cisplatin in combination with gemcitabin in patients with pancreatic cancer in Asia

Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047

Biganzoli, 2002, doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III Trial, J Clin Oncol, 20, 3114, 10.1200/JCO.2002.11.005

Martin, 2008, Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer, J Natl Cancer Inst, 100, 805, 10.1093/jnci/djn151

Roche, 2006, Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial, J Clin Oncol, 24, 5664, 10.1200/JCO.2006.07.3916

Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149

Lipshultz, 2008, Anthracycline associated cardiotoxicity in survivors of childhood cancer, Heart, 94, 525, 10.1136/hrt.2007.136093

de Azambuja, 2009, Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study, J Clin Oncol, 27, 720, 10.1200/JCO.2008.17.2155

Harada, 2011, Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300, Cancer Sci, 102, 192, 10.1111/j.1349-7006.2010.01745.x

Takahashi, 2013, NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin, Cancer Sci, 104, 920, 10.1111/cas.12153

Dimou, 2012, Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer, Ther Adv Med Oncol, 5, 271, 10.1177/1758834012446008

Yasunaga, 2013, The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution, Sci Rep, 3, 3050, 10.1038/srep03050

Matsumura, 2011, Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect, Adv Drug Deliv Rev, 63, 184, 10.1016/j.addr.2010.05.008

Hamaguchi, 2010, Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors, Clin Cancer Res, 16, 5058, 10.1158/1078-0432.CCR-10-0387

Nakajima, 2008, Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil, Int J Cancer, 122, 2148, 10.1002/ijc.23381

Nagano, 2009, Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment, Clin Cancer Res, 15, 4348, 10.1158/1078-0432.CCR-08-3334

Nagano, 2010, Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer, Int J Cancer, 127, 2699, 10.1002/ijc.25282

Na, 2010, Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model, Int J Pharm, 383, 192, 10.1016/j.ijpharm.2009.08.041

Yamamoto, 2014, Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model, Int J Cancer, 10.1002/ijc.28651

Xiao, 2012, Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy, J Control Release, 163, 304, 10.1016/j.jconrel.2012.06.004

Feldman, 2011, First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia, J Clin Oncol, 29, 979, 10.1200/JCO.2010.30.5961

Parhi, 2012, Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy, Drug Discov Today, 17, 1044, 10.1016/j.drudis.2012.05.010

Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat Biotech, 26, 925, 10.1038/nbt.1480